Major depressive disorder and peptides — what the trial record actually supports

Why this dossier exists

Major depressive disorder is the indication where the gap between popular peptide claims and the controlled-trial record is most asymmetric in either direction — most marketed peptide pharmacology has not been tested in MDD at all, and the most-tested peptide class (GLP-1 receptor agonists) has been associated with both anti-depressant and pro-depressant signals depending on which study design is asked. The WHO 2023 Depressive Disorder Fact Sheet estimates approximately 280 million people worldwide live with depression — a figure consistent with the Global Burden of Disease 2019 estimate and a substantial revision upward after the COVID-19 pandemic added an estimated 53.2 million new MDD cases in 2020. MDD is the single largest contributor to global years-lived-with-disability across mental health disorders. None of the peptide entries in this dossier are competitive with standard-of-care antidepressant pharmacology for primary MDD treatment.

The 2026 depression standard of care is set by four classes layered on top of psychotherapy: SSRIs and SNRIs (sertraline, escitalopram, fluoxetine, venlafaxine, duloxetine) as first-line pharmacotherapy with broad efficacy in mild-to-moderate MDD and substantial sexual-side-effect and discontinuation-syndrome footprints; atypical antipsychotic augmenters (aripiprazole, brexpiprazole, quetiapine) for partial responders; the rapid-acting NMDA-receptor antagonist class anchored by esketamine (Spravato), FDA-approved on 5 March 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy and granted standalone-use approval on 21 January 2025; and neurostimulation tools — TMS and ECT — for medication-refractory presentations. Psychotherapy delivered by trained clinicians, particularly CBT and interpersonal therapy, has the largest cumulative trial body of any single MDD intervention — the Cuijpers et al. 2023 World Psychiatry meta-analysis pooled 409 trials and 52,702 patients. The Compass Pathways COMP005 Phase 3 of COMP360 psilocybin hit its primary endpoint for TRD in 2025; confirmatory COMP006 is expected in 2026. Psilocybin is not a peptide and is treated here only as adjacent context that the depression pharmacopeia is in active expansion.

What brings peptides into the MDD conversation in 2026 is the GLP-1 receptor agonist class — and almost nothing else with comparable evidence depth. The Russian peptide cluster of Selank and Semax has anxiolytic and nootropic indications under domestic regulatory approval with thin Western validation. Oxytocin sits on a contested replication record for any CNS effect at intranasal doses, with the SOARS-B autism Phase 3 being the most rigorous trial ever conducted and the trial that failed. Kisspeptin has limbic-circuit modulation signals from the Imperial College group but the prespecified anxiety endpoints in the most recent placebo-controlled trial were uniformly null. Cerebrolysin has secondary mood-symptom signals in post-stroke cohorts. PT-141 is approved for hypoactive sexual desire disorder and intersects with depression through the SSRI-induced-sexual-dysfunction adjacency rather than any direct antidepressant claim. The honest one-line read: every peptide in this dossier operates downstream of either evidence-based antidepressant pharmacotherapy or evidence-based psychotherapy, not as a substitute for either.